Vyant Bio : attends the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 8th to 11th 2023

Fueling CNS drug discovery and development with the

power of understanding human biology.

Safe Harbor

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that exist in our operations and business environment, which may be beyond our control, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward- looking statements. For example, forward-looking statements include, without limitation: statements pertaining to Vyant Bio, Inc.'s expectations regarding future financial and/or operating results, the efficacy of our drug screening and discovery process, potential for our services, future revenues or growth and plans, strategies and objectives of management for future operations or transactions. The risks and uncertainties referred to above include, but are not limited to, risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2021 and any subsequent filings. These risks could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, Vyant Bio. Forward-looking statements

represent the judgment of the Company's management regarding future events. Although the we believe that the

expectations reflected in such forward-looking statements are reasonable at the time that they are made, we can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable law, the Company assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

©2022 Vyant Bio. Confidential. Nasdaq: VYNT	2

Our disease-first approach leverages the power of understanding human biology

to de-risk the CNS drug discovery and

development process.

3

Challenges

Neurological disease treatments are notoriously difficult and time-intensive to develop

of the world's population suffers	of all rare diseases are neurological,	of neurological disease drugs fail,
from a neurological disorder	and many are orphan diseases	often due to efficacy

©2022 Vyant Bio. Confidential. Nasdaq: VYNT	4

Challenges

The target-based approach needs a major paradigm shift

Target Validation is:

•	Costly and resource-draining	• Separate from safety testing
•	Inefficient	• Prone to legal and
•	Outdated	intellectual property issues

Potential compounds make it from discovery to the clinic

©2022 Vyant Bio. Confidential. Nasdaq: VYNT	5